

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:

NEW ASSIGNMENT

NATURE OF CONVEYANCE:

SECURITY AGREEMENT

CONVEYING PARTY DATA

Name	Execution Date
Exagen Diagnostics, Inc.	01/26/2007

RECEIVING PARTY DATA

Name:	Tullis-Dickerson Capital Focus III, L.P.
Street Address:	Two Greenwich Plaza, 4th Floor
City:	Greenwich
State/Country:	CONNECTICUT
Postal Code:	06830

PROPERTY NUMBERS Total: 15

Property Type	Number
Application Number:	60516817
Application Number:	10981277
Application Number:	60564758
Application Number:	60575978
Application Number:	60631702
Application Number:	60633826
Application Number:	60564757
Application Number:	11112908
Application Number:	60583568
Application Number:	11159799
Application Number:	60677765
Application Number:	11417450
Application Number:	60666000
Application Number:	11112926
Application Number:	11112944

PATENT

500217396

REEL: 018849 FRAME: 0316

CH \$600.00 60516817

CORRESPONDENCE DATA

Fax Number: (214)855-4300

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Email: jmuennink@jenkens.com

Correspondent Name: Cathryn A. Berryman

Address Line 1: 1445 Ross Avenue, Suite 3700

Address Line 4: Dallas, TEXAS 75202

ATTORNEY DOCKET NUMBER:

69299-2

NAME OF SUBMITTER:

Cathryn A. Berryman

Total Attachments: 15

source=Exagen patents assgn#page1.tif

source=Exagen patents assgn#page2.tif

source=Exagen patents assgn#page3.tif

source=Exagen patents assgn#page4.tif

source=Exagen patents assgn#page5.tif

source=Exagen patents assgn#page6.tif

source=Exagen patents assgn#page7.tif

source=Exagen patents assgn#page8.tif

source=Exagen patents assgn#page9.tif

source=Exagen patents assgn#page10.tif

source=Exagen patents assgn#page11.tif

source=Exagen patents assgn#page12.tif

source=Exagen patents assgn#page13.tif

source=Exagen patents assgn#page14.tif

source=Exagen patents assgn#page15.tif

NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS
(Exagen Diagnostics, Inc.)

This NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS (this "Agreement"), dated as of January 26, 2007, is executed by and between Exagen Diagnostics, Inc., a Delaware corporation ("Debtor") and Tullis-Dickerson Capital Focus III, L.P., in its capacity as administrative agent ("Secured Party") pursuant to the Security Agreement described below.

RECITALS:

WHEREAS, pursuant to the terms of that certain Security Agreement, dated as of January 26, 2007, between Debtor and Secured Party (the "Security Agreement"), Debtor has granted to Secured Party, for the benefit of itself and certain lenders, a continuing lien on and security interest in all intellectual property of Debtor including, without limitation, all of Debtor's right, title and interest in, to and under all now owned and hereafter acquired patents and patent licenses, and all products and proceeds thereof.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Debtor hereby grants to Secured Party, for the benefit of itself and certain lenders, a lien on and continuing security interest in all of Debtor's right, title and interest in, to, and under the following (all of the following items or types of property being herein collectively referred to as the "Patent Collateral"), whether presently existing or hereafter created or acquired:

(a) (i) all letters patent of the United States or any other country and all reissues and extensions thereof, including, without limitation, any letters patent referred to in Schedule 1 attached hereto, and (ii) all applications for letters patent of the United States or any other country and all divisions, continuations and continuations-in-part thereof including, without limitation, any thereof referred to in Schedule 1 attached hereto (collectively, "Patents");

(b) all agreements, whether written or oral, providing for the grant by or to Debtor of any right to manufacture, use or sell any invention covered by a Patent (collectively, "Patent Licenses"); and

(c) all products and proceeds of the foregoing, including, without limitation, any claim by Debtor against third parties for past, present or future infringement or breach of any Patent or Patent License.


The lien and security interest contained in this Agreement is granted in conjunction with the security interests granted to Secured Party, for the benefit of itself and certain lenders, pursuant to the Security Agreement. Debtor hereby acknowledges and affirms that the rights and remedies of Secured Party with respect to the security interests in the Patent Collateral made and granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.

IN WITNESS WHEREOF, Debtor has caused this Agreement to be duly executed by its duly authorized officer as of the 26 day of January, 2007.

DEBTOR:

EXAGEN DIAGNOSTICS, INC.

By: _____


James A. McClintic,
Chief Executive Officer

SECURED PARTY:

TULLIS-DICKERSON CAPITAL FOCUS III, L.P.

By: Tullis-Dickerson Partners III, L.L.C.,
its general partner

By: _____

Thomas P. Dickerson, Principal

IN WITNESS WHEREOF, Debtor has caused this Agreement to be duly executed by its duly authorized officer as of the 26 day of January, 2007.

DEBTOR:


EXAGEN DIAGNOSTICS, INC.

By: _____
James A. McClintic,
Chief Executive Officer

SECURED PARTY:

TULLIS-DICKERSON CAPITAL FOCUS III, L.P.

By: Tullis-Dickerson Partners III, L.L.C.,
its general partner

By:  _____
Thomas P. Dickerson, Principal

STATE OF TEXAS)
)
COUNTY OF TRAVIS)

This instrument was acknowledged before me this 26th day of January, 2007, by James A. McClintic, Chief Executive Officer of Exagen Diagnostics, Inc., a Delaware corporation, on behalf of such entity.

{Seal}  Leslie Glasper
Notary Public in and for the State of Texas

My commission expires: _____

STATE OF CONNECTICUT)
)
COUNTY OF _____)

This instrument was acknowledged before me this ____ day of January, 2007, by Thomas P. Dickerson, Principal of Tullis-Dickerson Partners III, L.L.C., the general partner of Tullis-Dickerson Capital Focus III, L.P., a Delaware limited partnership, on behalf of such entity.

{Seal} _____
Notary Public in and for the State of Connecticut

My commission expires: _____

STATE OF TEXAS)
)
COUNTY OF TRAVIS)

This instrument was acknowledged before me this ____ day of January, 2007, by James A. McClintic, Chief Executive Officer of Exagen Diagnostics, Inc., a Delaware corporation, on behalf of such entity.

{Seal}

Notary Public in and for the State of Texas

My commission expires: _____

STATE OF CONNECTICUT)
)
COUNTY OF Fairfield)

This instrument was acknowledged before me this 26th day of January, 2007, by Thomas P. Dickerson, Principal of Tullis-Dickerson Partners III, L.L.C., the general partner of Tullis-Dickerson Capital Focus III, L.P., a Delaware limited partnership, on behalf of such entity.

{Seal}

Regina M. Lupo

Notary Public in and for the State of Connecticut
REGINA M. LUPO
NOTARY PUBLIC
MY COMMISSION EXPIRES 9/30/2009

My commission expires: 9/30/2009

Schedule 1

See attached list.

Patent List

Monday, January 29, 2007

Client: EXAG Exagen Corporation

Case Number/Subcase Country Name	Case Type	Application Number/Date	Publication Number/Date	Patent Number/Date	Status	Expiration Date
----------------------------------	-----------	-------------------------	-------------------------	--------------------	--------	-----------------

03-968/ United States of America	PRO	60/516817 03-Nov-2003			Inactive	
Owner Name: Exagen Corporation						
Agent Name:						
Title: Compositions and Methods for Glioma Classification						
Attorney(s): DSH CPS						
Client Ref:						
Agent Ref:						

03-968/US United States of America	ORD	10/981277 03-Nov-2004	05-0181389 18-Aug-2005		Published	
Owner Name: Exagen Corporation						
Agent Name:						
Title: Compositions and Methods for Glioma Classification						
Attorney(s): DSH CPS						
Client Ref:						
Agent Ref:						

Patent List

Monday, January 29, 2007

Client: EXAG Exagen Corporation

Case Number/Subcase Country Name	Case Type	Application Number/Date	Publication Number/Date	Patent Number/Date	Status Expiration Date
04-164/EP European Patent Convention	PCT	05744871.4 22-Apr-2005			Published
Owner Name: Exagen Corporation					
Agent Name: Dr. Volker Vossius					
Title: Breast Cancer Biomarkers					

Attorney(s): DSH AFB
Client Ref:
Agent Ref: 150-243

04-164/IN India	PCT	3019/KOLNP/2006 18-Oct-2006			Pending
Owner Name: Exagen Corporation					
Agent Name: K & S Partners					
Title: Breast Cancer Biomarkers					

Attorney(s): DSH AFB
Client Ref:
Agent Ref: IP04497/GAK

04-164/JIP Japan	PCT	506147397 13-Nov-2006			Pending
Owner Name: Exagen Corporation					
Agent Name: ONDA TECHNO International Patent Attorneys					
Title: Breast Cancer Biomarkers					

Attorney(s): DSH AFB
Client Ref:
Agent Ref: PF 06014

Patent List

Monday, January 29, 2007

Client: EXAG Exagen Corporation

Case Number/Subcase Country Name	Case Type	Application Number/Date	Publication Number/Date	Patent Number/Date	Status Expiration Date
04-164/PCT Patent Cooperation Treaty	ORD	US05/014343 22-Apr-2005	W05/106044 10-Nov-2005		Entered Na

Owner Name: Exagen Corporation

Agent Name:
Title: Breast Cancer Biomarkers

Attorney(s): DSH AFB
Client Ref:
Agent Ref:

04-164/
United States of America

PRO 60/564758
23-Apr-2004

Owner Name: Exagen Corporation

Agent Name:
Title: Breast Cancer Biomarkers

Inactive
23-Apr-2005

Attorney(s): DSH AFB
Client Ref:
Agent Ref:

04-164/A
United States of America

PRO 60/575978
01-Jun-2004

Owner Name: Exagen Corporation

Agent Name:
Title: Breast Cancer Biomarkers

Inactive
01-Jun-2005

Attorney(s): DSH AFB
Client Ref:
Agent Ref:

Patent List

Monday, January 29, 2007

Client: EXAG Exagen Corporation

Case Number/Subcase Country Name	Case Type	Application Number/Date	Publication Number/Date	Patent Number/Date	Status Expiration Date
04-164/B United States of America	PRO	60/631702 30-Nov-2004			Inactive 30-Nov-2005
Owner Name: Exagen Corporation					
Agent Name:					
Title: Breast Cancer Biomarkers					

Attorney(s): DSH AFB
Client Ref:
Agent Ref:

04-164/C United States of America	PRO	60/633826 07-Dec-2004			Inactive 07-Dec-2005
Owner Name: Exagen Corporation					
Agent Name:					
Title: Breast Cancer Biomarkers					

Attorney(s): DSH AFB
Client Ref:
Agent Ref:

Patent List

Monday, January 29, 2007

Client: EXAG Exagen Corporation

Case Number/Subcase Country Name	Case Type	Application Number/Date	Publication Number/Date	Patent Number/Date	Status Expiration Date
04-164/PR2 United States of America	PRO	60/564757 23-Apr-2004			Inactive 23-Apr-2005

Owner Name: Exagen Corporation
Agent Name:
Title: Breast Cancer Biomarkers

Attorney(s): DSH AFB
Client Ref:
Agent Ref:

04-164/US United States of America	ORD	11/112908 22-Apr-2005	2005-0260659 24-Nov-2005		Published
---------------------------------------	-----	--------------------------	-----------------------------	--	-----------

Owner Name: Exagen Corporation
Agent Name:
Title: Breast Cancer Biomarkers

Attorney(s): DSH AFB
Client Ref:
Agent Ref:

Patent List

Monday, January 29, 2007

Client: EXAG Exagen Corporation

Case Number/Subcase Country Name	Case Type	Application Number/Date	Publication Number/Date	Patent Number/Date	Status Expiration Date
04-165/ United States of America	PRO	60/583568 28-Jun-2004			Inactive 28-Jun-2005

Owner Name: Exagen Corporation
Agent Name:
Title: Methods for RNA Fluorescence In Situ Hybridization

Attorney(s): DSH AFB
Client Ref:
Agent Ref:

04-165/US United States of America	ORD	11/159799 23-Jun-2005	US2005-0287578 29-Dec-2005		Published
---------------------------------------	-----	--------------------------	-------------------------------	--	-----------

Owner Name: Exagen Corporation
Agent Name:
Title: Methods for RNA Fluorescence In Situ Hybridization

Attorney(s): DSH AFB
Client Ref:
Agent Ref:

05-116/PCT Patent Cooperation Treaty	ORD	US06/17371 03-May-2006	Wo2006/119494 09-Nov-2006		Published
---	-----	---------------------------	------------------------------	--	-----------

Owner Name: Exagen Corporation
Agent Name:
Title: Acute Myelogenous Leukemia Biomarkers

Attorney(s): DSH AFB
Client Ref:
Agent Ref:

Patent List

Monday, January 29, 2007

Client: EXAG Exagen Corporation

Case Number/Subcase Country Name	Case Type	Application Number/Date	Publication Number/Date	Patent Number/Date	Status	Expiration Date
05-116/ United States of America	PRO	60/677765 04-May-2005			Inactive	04-May-2006
Owner Name: Exagen Corporation			Attorney(s): DSH AFB			
Agent Name:			Client Ref:			
Title: Acute Myelogenous Leukemia Biomarkers			Agent Ref:			

05-116/US United States of America	ORD	11/417450 03-May-2006	US-2006-0281107-A1 14-Dec-2006		Published	
Owner Name: Exagen Corporation			Attorney(s): DSH AFB			
Agent Name:			Client Ref:			
Title: Acute Myelogenous Leukemia Biomarkers			Agent Ref:			

05-218/PCT Patent Cooperation Treaty	ORD	US06/10195 20-Mar-2006	WO2006/104761 05-Oct-2006		Published	
Owner Name: Exagen Corporation			Attorney(s): DSH AFB			
Agent Name:			Client Ref:			
Title: Unique Sequence Hybridization Probes			Agent Ref:			

Patent List

Monday, January 29, 2007

Client: EXAG Exagen Corporation

Case Number/Subcase Country Name	Case Type	Application Number/Date	Publication Number/Date	Patent Number/Date	Status	Expiration Date
05-218/ United States of America	PRO	60/666000 29-Mar-2005			Inactive	29-Mar-2006

Owner Name: Exagen Corporation
Attorney(s): DSH AFB
Client Ref:
Agent Ref:

Agent Name:

Title: Unique Sequence Hybridization Probes

05-218/US United States of America	ORD	11/112926 22-Apr-2005	US-2006-0223075-A1 05-Oct-2006		Published	
---------------------------------------	-----	--------------------------	-----------------------------------	--	-----------	--

Owner Name: Exagen Corporation
Attorney(s): DSH AFB
Client Ref:
Agent Ref:

Agent Name:

Title: Unique Sequence Hybridization Probes

05-325/EP European Patent Convention	PCT	05740216.6 22-Apr-2005	1737981 03-Jan-2007		Published	
---	-----	---------------------------	------------------------	--	-----------	--

Owner Name: Exagen Corporation
Attorney(s): DSH AFB
Client Ref:
Agent Ref: 150-245

Agent Name: Dr. Volker Vossius

Title: Breast Cancer Gene Expression Biomarkers

PATENT

REEL: 018849 FRAME: 0331

Patent List

Monday, January 29, 2007

Client: EXAG Exagen Corporation

Case Number/Subcase Country Name	Case Type	Application Number/Date	Publication Number/Date	Patent Number/Date	Status Expiration Date
05-325/JP Japan	PCT	tbd 13-Oct-2006			Pending
Owner Name: Exagen Corporation					
Agent Name: ONDA TECHNO International Patent Attorneys					
Title: Breast Cancer Gene Expression Biomarkers					

Attorney(s): DSH AFB
Client Ref:
Agent Ref:

Attorney(s): DSH AFB
Client Ref:
Agent Ref:

W05/106043
10-Nov-2005

ORD US05/14341
22-Apr-2005
Owner Name: Exagen Corporation

Agent Name:
Title: Breast Cancer Gene Expression Biomarkers

05-325/PCT
Patent Cooperation Treaty

Entered Na

Attorney(s): DSH AFB
Client Ref:
Agent Ref:

US-2005-0244872
03-Nov-2005

ORD 11/112944
22-Apr-2005
Owner Name: Exagen Corporation

Agent Name:
Title: Breast Cancer Gene Expression Biomarkers

05-325/US
United States of America

Published